表紙
市場調查報告書

腎臟癌治療藥的全球市場

Kidney Cancer Drugs

出版商 Global Industry Analysts, Inc. 商品編碼 912816
出版日期 內容資訊 英文 243 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
腎臟癌治療藥的全球市場 Kidney Cancer Drugs
出版日期: 2019年10月01日內容資訊: 英文 243 Pages
簡介

本報告提供全球腎臟癌治療藥市場相關調查分析,提供市場概要,主要企業,市場趨勢·促進因素,全球市場預測,各地區市場分析,競爭情形相關的系統性資訊。

第1章 調查手法

第2章 摘要整理

  • 市場概要
    • 全球市場的企業佔有率
    • 全球腎臟癌治療藥市場上企業佔有率方案
  • 主要企業
  • 市場趨勢與發展因素
  • 全球市場預測

第3章 市場分析

  • 各地區市場分析
    • 美國
    • 加拿大
    • 日本
    • 中國
    • 歐洲
    • 法國
    • 德國
    • 義大利
    • 英國
    • 西班牙
    • 俄羅斯
    • 其他歐洲
    • 亞太地區
    • 澳洲
    • 印度
    • 韓國
    • 其他亞太地區
    • 南美
    • 阿根廷
    • 巴西
    • 墨西哥
    • 其他南美國家
    • 中東
    • 伊朗
    • 以色列
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東
    • 非洲

第4章 競爭企業

  • BAYER AG
  • BRISTOL-MYERS SQUIBB COMPANY
  • Eisai
  • EXELIXIS, INC.
  • NOVARTIS INTERNATIONAL AG
  • PFIZER, INC

第5章 調查資料

目錄
Product Code: MCP-6797

Kidney Cancer Drugs market worldwide is projected to grow by US$2 Billion, driven by a compounded growth of 5.1%. Targeted Therapy, one of the segments analyzed and sized in this study, displays the potential to grow at over 5.4%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$4.6 Billion by the year 2025, Targeted Therapy will bring in healthy gains adding significant momentum to global growth.

Representing the developed world, the United States will maintain a 3.9% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$68.8 Million to the region's size and clout in the next 5 to 6 years. Over US$56.1 Million worth of projected demand in the region will come from Rest of Europe markets. In Japan, Targeted Therapy will reach a market size of US$250.7 Million by the close of the analysis period. As the world's second largest economy and the new game changer in global markets, China exhibits the potential to grow at 8.2% over the next couple of years and add approximately US$584.8 Million in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders. Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

Competitors identified in this market include, among others,, Bayer AG; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Exelixis, Inc.; Novartis International AG; Pfizer, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Global Competitor Market Shares
  • Kidney Cancer Drugs Competitor Market Share Scenario Worldwide (in %): 2019 & 2028

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

  • TABLE 1: Kidney Cancer Drugs Global Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025
  • TABLE 2: Kidney Cancer Drugs Global Retrospective Market Scenario in US$ Million by Region/Country: 2009-2017
  • TABLE 3: Kidney Cancer Drugs Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025
  • TABLE 4: Targeted Therapy (Therapeutic Class) World Market by Region/Country in US$ Million: 2018 to 2025
  • TABLE 5: Targeted Therapy (Therapeutic Class) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017
  • TABLE 6: Targeted Therapy (Therapeutic Class) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025
  • TABLE 7: Immunotherapy (Therapeutic Class) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025
  • TABLE 8: Immunotherapy (Therapeutic Class) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017
  • TABLE 9: Immunotherapy (Therapeutic Class) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025
  • TABLE 10: Angiogenesis Inhibitors (Pharmacologic Class) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025
  • TABLE 11: Angiogenesis Inhibitors (Pharmacologic Class) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017
  • TABLE 12: Angiogenesis Inhibitors (Pharmacologic Class) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025
  • TABLE 13: mTOR Inhibitors (Pharmacologic Class) World Market Estimates and Forecasts by Region/Country in US$ Million: 2018 to 2025
  • TABLE 14: mTOR Inhibitors (Pharmacologic Class) Market Historic Review by Region/Country in US$ Million: 2009 to 2017
  • TABLE 15: mTOR Inhibitors (Pharmacologic Class) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025
  • TABLE 16: Monoclonal Antibodies (Pharmacologic Class) World Market by Region/Country in US$ Million: 2018 to 2025
  • TABLE 17: Monoclonal Antibodies (Pharmacologic Class) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017
  • TABLE 18: Monoclonal Antibodies (Pharmacologic Class) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025
  • TABLE 19: Cytokine Immunotherapy (IL-2) (Pharmacologic Class) World Market Estimates and Forecasts in US$ Million by Region/Country: 2018 to 2025
  • TABLE 20: Cytokine Immunotherapy (IL-2) (Pharmacologic Class) Market Worldwide Historic Review by Region/Country in US$ Million: 2009 to 2017
  • TABLE 21: Cytokine Immunotherapy (IL-2) (Pharmacologic Class) Market Percentage Share Distribution by Region/Country: 2009 VS 2019 VS 2025

III. MARKET ANALYSIS

  • GEOGRAPHIC MARKET ANALYSIS
  • UNITED STATES
    • Market Facts & Figures
    • US Kidney Cancer Drugs Market Share (in %) by Company: 2019 & 2025
    • TABLE 22: United States Kidney Cancer Drugs Market Estimates and Projections in US$ Million by Therapeutic Class: 2018 to 2025
    • TABLE 23: Kidney Cancer Drugs Market in the United States by Therapeutic Class: A Historic Review in US$ Million for 2009-2017
    • TABLE 24: United States Kidney Cancer Drugs Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025
    • TABLE 25: United States Kidney Cancer Drugs Market Estimates and Projections in US$ Million by Pharmacologic Class: 2018 to 2025
    • TABLE 26: Kidney Cancer Drugs Market in the United States by Pharmacologic Class: A Historic Review in US$ Million for 2009-2017
    • TABLE 27: United States Kidney Cancer Drugs Market Share Breakdown by Pharmacologic Class: 2009 VS 2019 VS 2025
  • CANADA
    • TABLE 28: Canadian Kidney Cancer Drugs Market Estimates and Forecasts in US$ Million by Therapeutic Class: 2018 to 2025
    • TABLE 29: Canadian Kidney Cancer Drugs Historic Market Review by Therapeutic Class in US$ Million: 2009-2017
    • TABLE 30: Kidney Cancer Drugs Market in Canada: Percentage Share Breakdown of Sales by Therapeutic Class for 2009, 2019, and 2025
    • TABLE 31: Canadian Kidney Cancer Drugs Market Estimates and Forecasts in US$ Million by Pharmacologic Class: 2018 to 2025
    • TABLE 32: Canadian Kidney Cancer Drugs Historic Market Review by Pharmacologic Class in US$ Million: 2009-2017
    • TABLE 33: Kidney Cancer Drugs Market in Canada: Percentage Share Breakdown of Sales by Pharmacologic Class for 2009, 2019, and 2025
  • JAPAN
    • TABLE 34: Japanese Market for Kidney Cancer Drugs: Annual Sales Estimates and Projections in US$ Million by Therapeutic Class for the Period 2018-2025
    • TABLE 35: Kidney Cancer Drugs Market in Japan: Historic Sales Analysis in US$ Million by Therapeutic Class for the Period 2009-2017
    • TABLE 36: Japanese Kidney Cancer Drugs Market Share Analysis by Therapeutic Class: 2009 VS 2019 VS 2025
    • TABLE 37: Japanese Market for Kidney Cancer Drugs: Annual Sales Estimates and Projections in US$ Million by Pharmacologic Class for the Period 2018-2025
    • TABLE 38: Kidney Cancer Drugs Market in Japan: Historic Sales Analysis in US$ Million by Pharmacologic Class for the Period 2009-2017
    • TABLE 39: Japanese Kidney Cancer Drugs Market Share Analysis by Pharmacologic Class: 2009 VS 2019 VS 2025
  • CHINA
    • TABLE 40: Chinese Kidney Cancer Drugs Market Growth Prospects in US$ Million by Therapeutic Class for the Period 2018-2025
    • TABLE 41: Kidney Cancer Drugs Historic Market Analysis in China in US$ Million by Therapeutic Class: 2009-2017
    • TABLE 42: Chinese Kidney Cancer Drugs Market by Therapeutic Class: Percentage Breakdown of Sales for 2009, 2019, and 2025
    • TABLE 43: Chinese Kidney Cancer Drugs Market Growth Prospects in US$ Million by Pharmacologic Class for the Period 2018-2025
    • TABLE 44: Kidney Cancer Drugs Historic Market Analysis in China in US$ Million by Pharmacologic Class: 2009-2017
    • TABLE 45: Chinese Kidney Cancer Drugs Market by Pharmacologic Class: Percentage Breakdown of Sales for 2009, 2019, and 2025
  • EUROPE
    • Market Facts & Figures
    • European Kidney Cancer Drugs Market: Competitor Market Share Scenario (in %) for 2019 & 2025
    • TABLE 46: European Kidney Cancer Drugs Market Demand Scenario in US$ Million by Region/Country: 2018-2025
    • TABLE 47: Kidney Cancer Drugs Market in Europe: A Historic Market Perspective in US$ Million by Region/Country for the Period 2009-2017
    • TABLE 48: European Kidney Cancer Drugs Market Share Shift by Region/Country: 2009 VS 2019 VS 2025
    • TABLE 49: European Kidney Cancer Drugs Market Estimates and Forecasts in US$ Million by Therapeutic Class: 2018-2025
    • TABLE 50: Kidney Cancer Drugs Market in Europe in US$ Million by Therapeutic Class: A Historic Review for the Period 2009-2017
    • TABLE 51: European Kidney Cancer Drugs Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025
    • TABLE 52: European Kidney Cancer Drugs Market Estimates and Forecasts in US$ Million by Pharmacologic Class: 2018-2025
    • TABLE 53: Kidney Cancer Drugs Market in Europe in US$ Million by Pharmacologic Class: A Historic Review for the Period 2009-2017
    • TABLE 54: European Kidney Cancer Drugs Market Share Breakdown by Pharmacologic Class: 2009 VS 2019 VS 2025
  • FRANCE
    • TABLE 55: Kidney Cancer Drugs Market in France by Therapeutic Class: Estimates and Projections in US$ Million for the Period 2018-2025
    • TABLE 56: French Kidney Cancer Drugs Historic Market Scenario in US$ Million by Therapeutic Class: 2009-2017
    • TABLE 57: French Kidney Cancer Drugs Market Share Analysis by Therapeutic Class: 2009 VS 2019 VS 2025
    • TABLE 58: Kidney Cancer Drugs Market in France by Pharmacologic Class: Estimates and Projections in US$ Million for the Period 2018-2025
    • TABLE 59: French Kidney Cancer Drugs Historic Market Scenario in US$ Million by Pharmacologic Class: 2009-2017
    • TABLE 60: French Kidney Cancer Drugs Market Share Analysis by Pharmacologic Class: 2009 VS 2019 VS 2025
  • GERMANY
    • TABLE 61: Kidney Cancer Drugs Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Therapeutic Class for the Period 2018-2025
    • TABLE 62: German Kidney Cancer Drugs Historic Market Analysis in US$ Million by Therapeutic Class: 2009-2017
    • TABLE 63: German Kidney Cancer Drugs Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025
    • TABLE 64: Kidney Cancer Drugs Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Pharmacologic Class for the Period 2018-2025
    • TABLE 65: German Kidney Cancer Drugs Historic Market Analysis in US$ Million by Pharmacologic Class: 2009-2017
    • TABLE 66: German Kidney Cancer Drugs Market Share Breakdown by Pharmacologic Class: 2009 VS 2019 VS 2025
  • ITALY
    • TABLE 67: Italian Kidney Cancer Drugs Market Growth Prospects in US$ Million by Therapeutic Class for the Period 2018-2025
    • TABLE 68: Kidney Cancer Drugs Historic Market Analysis in Italy in US$ Million by Therapeutic Class: 2009-2017
    • TABLE 69: Italian Kidney Cancer Drugs Market by Therapeutic Class: Percentage Breakdown of Sales for 2009, 2019, and 2025
    • TABLE 70: Italian Kidney Cancer Drugs Market Growth Prospects in US$ Million by Pharmacologic Class for the Period 2018-2025
    • TABLE 71: Kidney Cancer Drugs Historic Market Analysis in Italy in US$ Million by Pharmacologic Class: 2009-2017
    • TABLE 72: Italian Kidney Cancer Drugs Market by Pharmacologic Class: Percentage Breakdown of Sales for 2009, 2019, and 2025
  • UNITED KINGDOM
    • TABLE 73: United Kingdom Market for Kidney Cancer Drugs: Annual Sales Estimates and Projections in US$ Million by Therapeutic Class for the Period 2018-2025
    • TABLE 74: Kidney Cancer Drugs Market in the United Kingdom: Historic Sales Analysis in US$ Million by Therapeutic Class for the Period 2009-2017
    • TABLE 75: United Kingdom Kidney Cancer Drugs Market Share Analysis by Therapeutic Class: 2009 VS 2019 VS 2025
    • TABLE 76: United Kingdom Market for Kidney Cancer Drugs: Annual Sales Estimates and Projections in US$ Million by Pharmacologic Class for the Period 2018-2025
    • TABLE 77: Kidney Cancer Drugs Market in the United Kingdom: Historic Sales Analysis in US$ Million by Pharmacologic Class for the Period 2009-2017
    • TABLE 78: United Kingdom Kidney Cancer Drugs Market Share Analysis by Pharmacologic Class: 2009 VS 2019 VS 2025
  • SPAIN
    • TABLE 79: Spanish Kidney Cancer Drugs Market Estimates and Forecasts in US$ Million by Therapeutic Class: 2018 to 2025
    • TABLE 80: Spanish Kidney Cancer Drugs Historic Market Review by Therapeutic Class in US$ Million: 2009-2017
    • TABLE 81: Kidney Cancer Drugs Market in Spain: Percentage Share Breakdown of Sales by Therapeutic Class for 2009, 2019, and 2025
    • TABLE 82: Spanish Kidney Cancer Drugs Market Estimates and Forecasts in US$ Million by Pharmacologic Class: 2018 to 2025
    • TABLE 83: Spanish Kidney Cancer Drugs Historic Market Review by Pharmacologic Class in US$ Million: 2009-2017
    • TABLE 84: Kidney Cancer Drugs Market in Spain: Percentage Share Breakdown of Sales by Pharmacologic Class for 2009, 2019, and 2025
  • RUSSIA
    • TABLE 85: Russian Kidney Cancer Drugs Market Estimates and Projections in US$ Million by Therapeutic Class: 2018 to 2025
    • TABLE 86: Kidney Cancer Drugs Market in Russia by Therapeutic Class: A Historic Review in US$ Million for 2009-2017
    • TABLE 87: Russian Kidney Cancer Drugs Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025
    • TABLE 88: Russian Kidney Cancer Drugs Market Estimates and Projections in US$ Million by Pharmacologic Class: 2018 to 2025
    • TABLE 89: Kidney Cancer Drugs Market in Russia by Pharmacologic Class: A Historic Review in US$ Million for 2009-2017
    • TABLE 90: Russian Kidney Cancer Drugs Market Share Breakdown by Pharmacologic Class: 2009 VS 2019 VS 2025
  • REST OF EUROPE
    • TABLE 91: Rest of Europe Kidney Cancer Drugs Market Estimates and Forecasts in US$ Million by Therapeutic Class: 2018-2025
    • TABLE 92: Kidney Cancer Drugs Market in Rest of Europe in US$ Million by Therapeutic Class: A Historic Review for the Period 2009-2017
    • TABLE 93: Rest of Europe Kidney Cancer Drugs Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025
    • TABLE 94: Rest of Europe Kidney Cancer Drugs Market Estimates and Forecasts in US$ Million by Pharmacologic Class: 2018-2025
    • TABLE 95: Kidney Cancer Drugs Market in Rest of Europe in US$ Million by Pharmacologic Class: A Historic Review for the Period 2009-2017
    • TABLE 96: Rest of Europe Kidney Cancer Drugs Market Share Breakdown by Pharmacologic Class: 2009 VS 2019 VS 2025
  • ASIA-PACIFIC
    • TABLE 97: Asia-Pacific Kidney Cancer Drugs Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025
    • TABLE 98: Kidney Cancer Drugs Market in Asia-Pacific: Historic Market Analysis in US$ Million by Region/Country for the Period 2009-2017
    • TABLE 99: Asia-Pacific Kidney Cancer Drugs Market Share Analysis by Region/Country: 2009 VS 2019 VS 2025
    • TABLE 100: Kidney Cancer Drugs Market in Asia-Pacific by Therapeutic Class: Estimates and Projections in US$ Million for the Period 2018-2025
    • TABLE 101: Asia-Pacific Kidney Cancer Drugs Historic Market Scenario in US$ Million by Therapeutic Class: 2009-2017
    • TABLE 102: Asia-Pacific Kidney Cancer Drugs Market Share Analysis by Therapeutic Class: 2009 VS 2019 VS 2025
    • TABLE 103: Kidney Cancer Drugs Market in Asia-Pacific by Pharmacologic Class: Estimates and Projections in US$ Million for the Period 2018-2025
    • TABLE 104: Asia-Pacific Kidney Cancer Drugs Historic Market Scenario in US$ Million by Pharmacologic Class: 2009-2017
    • TABLE 105: Asia-Pacific Kidney Cancer Drugs Market Share Analysis by Pharmacologic Class: 2009 VS 2019 VS 2025
  • AUSTRALIA
    • TABLE 106: Kidney Cancer Drugs Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Therapeutic Class for the Period 2018-2025
    • TABLE 107: Australian Kidney Cancer Drugs Historic Market Analysis in US$ Million by Therapeutic Class: 2009-2017
    • TABLE 108: Australian Kidney Cancer Drugs Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025
    • TABLE 109: Kidney Cancer Drugs Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Pharmacologic Class for the Period 2018-2025
    • TABLE 110: Australian Kidney Cancer Drugs Historic Market Analysis in US$ Million by Pharmacologic Class: 2009-2017
    • TABLE 111: Australian Kidney Cancer Drugs Market Share Breakdown by Pharmacologic Class: 2009 VS 2019 VS 2025
  • INDIA
    • TABLE 112: Indian Kidney Cancer Drugs Market Estimates and Forecasts in US$ Million by Therapeutic Class: 2018 to 2025
    • TABLE 113: Indian Kidney Cancer Drugs Historic Market Review by Therapeutic Class in US$ Million: 2009-2017
    • TABLE 114: Kidney Cancer Drugs Market in India: Percentage Share Breakdown of Sales by Therapeutic Class for 2009, 2019, and 2025
    • TABLE 115: Indian Kidney Cancer Drugs Market Estimates and Forecasts in US$ Million by Pharmacologic Class: 2018 to 2025
    • TABLE 116: Indian Kidney Cancer Drugs Historic Market Review by Pharmacologic Class in US$ Million: 2009-2017
    • TABLE 117: Kidney Cancer Drugs Market in India: Percentage Share Breakdown of Sales by Pharmacologic Class for 2009, 2019, and 2025
  • SOUTH KOREA
    • TABLE 118: Kidney Cancer Drugs Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Therapeutic Class for the Period 2018-2025
    • TABLE 119: South Korean Kidney Cancer Drugs Historic Market Analysis in US$ Million by Therapeutic Class: 2009-2017
    • TABLE 120: Kidney Cancer Drugs Market Share Distribution in South Korea by Therapeutic Class: 2009 VS 2019 VS 2025
    • TABLE 121: Kidney Cancer Drugs Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Pharmacologic Class for the Period 2018-2025
    • TABLE 122: South Korean Kidney Cancer Drugs Historic Market Analysis in US$ Million by Pharmacologic Class: 2009-2017
    • TABLE 123: Kidney Cancer Drugs Market Share Distribution in South Korea by Pharmacologic Class: 2009 VS 2019 VS 2025
  • REST OF ASIA-PACIFIC
    • TABLE 124: Rest of Asia-Pacific Market for Kidney Cancer Drugs: Annual Sales Estimates and Projections in US$ Million by Therapeutic Class for the Period 2018-2025
    • TABLE 125: Kidney Cancer Drugs Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Therapeutic Class for the Period 2009-2017
    • TABLE 126: Rest of Asia-Pacific Kidney Cancer Drugs Market Share Analysis by Therapeutic Class: 2009 VS 2019 VS 2025
    • TABLE 127: Rest of Asia-Pacific Market for Kidney Cancer Drugs: Annual Sales Estimates and Projections in US$ Million by Pharmacologic Class for the Period 2018-2025
    • TABLE 128: Kidney Cancer Drugs Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Pharmacologic Class for the Period 2009-2017
    • TABLE 129: Rest of Asia-Pacific Kidney Cancer Drugs Market Share Analysis by Pharmacologic Class: 2009 VS 2019 VS 2025
  • LATIN AMERICA
    • TABLE 130: Latin American Kidney Cancer Drugs Market Trends by Region/Country in US$ Million: 2018-2025
    • TABLE 131: Kidney Cancer Drugs Market in Latin America in US$ Million by Region/Country: A Historic Perspective for the Period 2009-2017
    • TABLE 132: Latin American Kidney Cancer Drugs Market Percentage Breakdown of Sales by Region/Country: 2009, 2019, and 2025
    • TABLE 133: Latin American Kidney Cancer Drugs Market Growth Prospects in US$ Million by Therapeutic Class for the Period 2018-2025
    • TABLE 134: Kidney Cancer Drugs Historic Market Analysis in Latin America in US$ Million by Therapeutic Class: 2009-2017
    • TABLE 135: Latin American Kidney Cancer Drugs Market by Therapeutic Class: Percentage Breakdown of Sales for 2009, 2019, and 2025
    • TABLE 136: Latin American Kidney Cancer Drugs Market Growth Prospects in US$ Million by Pharmacologic Class for the Period 2018-2025
    • TABLE 137: Kidney Cancer Drugs Historic Market Analysis in Latin America in US$ Million by Pharmacologic Class: 2009-2017
    • TABLE 138: Latin American Kidney Cancer Drugs Market by Pharmacologic Class: Percentage Breakdown of Sales for 2009, 2019, and 2025
  • ARGENTINA
    • TABLE 139: Argentinean Kidney Cancer Drugs Market Estimates and Forecasts in US$ Million by Therapeutic Class: 2018-2025
    • TABLE 140: Kidney Cancer Drugs Market in Argentina in US$ Million by Therapeutic Class: A Historic Review for the Period 2009-2017
    • TABLE 141: Argentinean Kidney Cancer Drugs Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025
    • TABLE 142: Argentinean Kidney Cancer Drugs Market Estimates and Forecasts in US$ Million by Pharmacologic Class: 2018-2025
    • TABLE 143: Kidney Cancer Drugs Market in Argentina in US$ Million by Pharmacologic Class: A Historic Review for the Period 2009-2017
    • TABLE 144: Argentinean Kidney Cancer Drugs Market Share Breakdown by Pharmacologic Class: 2009 VS 2019 VS 2025
  • BRAZIL
    • TABLE 145: Kidney Cancer Drugs Market in Brazil by Therapeutic Class: Estimates and Projections in US$ Million for the Period 2018-2025
    • TABLE 146: Brazilian Kidney Cancer Drugs Historic Market Scenario in US$ Million by Therapeutic Class: 2009-2017
    • TABLE 147: Brazilian Kidney Cancer Drugs Market Share Analysis by Therapeutic Class: 2009 VS 2019 VS 2025
    • TABLE 148: Kidney Cancer Drugs Market in Brazil by Pharmacologic Class: Estimates and Projections in US$ Million for the Period 2018-2025
    • TABLE 149: Brazilian Kidney Cancer Drugs Historic Market Scenario in US$ Million by Pharmacologic Class: 2009-2017
    • TABLE 150: Brazilian Kidney Cancer Drugs Market Share Analysis by Pharmacologic Class: 2009 VS 2019 VS 2025
  • MEXICO
    • TABLE 151: Kidney Cancer Drugs Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Therapeutic Class for the Period 2018-2025
    • TABLE 152: Mexican Kidney Cancer Drugs Historic Market Analysis in US$ Million by Therapeutic Class: 2009-2017
    • TABLE 153: Mexican Kidney Cancer Drugs Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025
    • TABLE 154: Kidney Cancer Drugs Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Pharmacologic Class for the Period 2018-2025
    • TABLE 155: Mexican Kidney Cancer Drugs Historic Market Analysis in US$ Million by Pharmacologic Class: 2009-2017
    • TABLE 156: Mexican Kidney Cancer Drugs Market Share Breakdown by Pharmacologic Class: 2009 VS 2019 VS 2025
  • REST OF LATIN AMERICA
    • TABLE 157: Rest of Latin America Kidney Cancer Drugs Market Estimates and Projections in US$ Million by Therapeutic Class: 2018 to 2025
    • TABLE 158: Kidney Cancer Drugs Market in Rest of Latin America by Therapeutic Class: A Historic Review in US$ Million for 2009-2017
    • TABLE 159: Rest of Latin America Kidney Cancer Drugs Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025
    • TABLE 160: Rest of Latin America Kidney Cancer Drugs Market Estimates and Projections in US$ Million by Pharmacologic Class: 2018 to 2025
    • TABLE 161: Kidney Cancer Drugs Market in Rest of Latin America by Pharmacologic Class: A Historic Review in US$ Million for 2009-2017
    • TABLE 162: Rest of Latin America Kidney Cancer Drugs Market Share Breakdown by Pharmacologic Class: 2009 VS 2019 VS 2025
  • MIDDLE EAST
    • TABLE 163: The Middle East Kidney Cancer Drugs Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025
    • TABLE 164: Kidney Cancer Drugs Market in the Middle East by Region/Country in US$ Million: 2009-2017
    • TABLE 165: The Middle East Kidney Cancer Drugs Market Share Breakdown by Region/Country: 2009, 2019, and 2025
    • TABLE 166: The Middle East Kidney Cancer Drugs Market Estimates and Forecasts in US$ Million by Therapeutic Class: 2018 to 2025
    • TABLE 167: The Middle East Kidney Cancer Drugs Historic Market by Therapeutic Class in US$ Million: 2009-2017
    • TABLE 168: Kidney Cancer Drugs Market in the Middle East: Percentage Share Breakdown of Sales by Therapeutic Class for 2009, 2019, and 2025
    • TABLE 169: The Middle East Kidney Cancer Drugs Market Estimates and Forecasts in US$ Million by Pharmacologic Class: 2018 to 2025
    • TABLE 170: The Middle East Kidney Cancer Drugs Historic Market by Pharmacologic Class in US$ Million: 2009-2017
    • TABLE 171: Kidney Cancer Drugs Market in the Middle East: Percentage Share Breakdown of Sales by Pharmacologic Class for 2009, 2019, and 2025
  • IRAN
    • TABLE 172: Iranian Market for Kidney Cancer Drugs: Annual Sales Estimates and Projections in US$ Million by Therapeutic Class for the Period 2018-2025
    • TABLE 173: Kidney Cancer Drugs Market in Iran: Historic Sales Analysis in US$ Million by Therapeutic Class for the Period 2009-2017
    • TABLE 174: Iranian Kidney Cancer Drugs Market Share Analysis by Therapeutic Class: 2009 VS 2019 VS 2025
    • TABLE 175: Iranian Market for Kidney Cancer Drugs: Annual Sales Estimates and Projections in US$ Million by Pharmacologic Class for the Period 2018-2025
    • TABLE 176: Kidney Cancer Drugs Market in Iran: Historic Sales Analysis in US$ Million by Pharmacologic Class for the Period 2009-2017
    • TABLE 177: Iranian Kidney Cancer Drugs Market Share Analysis by Pharmacologic Class: 2009 VS 2019 VS 2025
  • ISRAEL
    • TABLE 178: Israeli Kidney Cancer Drugs Market Estimates and Forecasts in US$ Million by Therapeutic Class: 2018-2025
    • TABLE 179: Kidney Cancer Drugs Market in Israel in US$ Million by Therapeutic Class: A Historic Review for the Period 2009-2017
    • TABLE 180: Israeli Kidney Cancer Drugs Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025
    • TABLE 181: Israeli Kidney Cancer Drugs Market Estimates and Forecasts in US$ Million by Pharmacologic Class: 2018-2025
    • TABLE 182: Kidney Cancer Drugs Market in Israel in US$ Million by Pharmacologic Class: A Historic Review for the Period 2009-2017
    • TABLE 183: Israeli Kidney Cancer Drugs Market Share Breakdown by Pharmacologic Class: 2009 VS 2019 VS 2025
  • SAUDI ARABIA
    • TABLE 184: Saudi Arabian Kidney Cancer Drugs Market Growth Prospects in US$ Million by Therapeutic Class for the Period 2018-2025
    • TABLE 185: Kidney Cancer Drugs Historic Market Analysis in Saudi Arabia in US$ Million by Therapeutic Class: 2009-2017
    • TABLE 186: Saudi Arabian Kidney Cancer Drugs Market by Therapeutic Class: Percentage Breakdown of Sales for 2009, 2019, and 2025
    • TABLE 187: Saudi Arabian Kidney Cancer Drugs Market Growth Prospects in US$ Million by Pharmacologic Class for the Period 2018-2025
    • TABLE 188: Kidney Cancer Drugs Historic Market Analysis in Saudi Arabia in US$ Million by Pharmacologic Class: 2009-2017
    • TABLE 189: Saudi Arabian Kidney Cancer Drugs Market by Pharmacologic Class: Percentage Breakdown of Sales for 2009, 2019, and 2025
  • UNITED ARAB EMIRATES
    • TABLE 190: Kidney Cancer Drugs Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Therapeutic Class for the Period 2018-2025
    • TABLE 191: United Arab Emirates Kidney Cancer Drugs Historic Market Analysis in US$ Million by Therapeutic Class: 2009-2017
    • TABLE 192: Kidney Cancer Drugs Market Share Distribution in United Arab Emirates by Therapeutic Class: 2009 VS 2019 VS 2025
    • TABLE 193: Kidney Cancer Drugs Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Pharmacologic Class for the Period 2018-2025
    • TABLE 194: United Arab Emirates Kidney Cancer Drugs Historic Market Analysis in US$ Million by Pharmacologic Class: 2009-2017
    • TABLE 195: Kidney Cancer Drugs Market Share Distribution in United Arab Emirates by Pharmacologic Class: 2009 VS 2019 VS 2025
  • REST OF MIDDLE EAST
    • TABLE 196: Kidney Cancer Drugs Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Therapeutic Class for the Period 2018-2025
    • TABLE 197: Rest of Middle East Kidney Cancer Drugs Historic Market Analysis in US$ Million by Therapeutic Class: 2009-2017
    • TABLE 198: Rest of Middle East Kidney Cancer Drugs Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025
    • TABLE 199: Kidney Cancer Drugs Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Pharmacologic Class for the Period 2018-2025
    • TABLE 200: Rest of Middle East Kidney Cancer Drugs Historic Market Analysis in US$ Million by Pharmacologic Class: 2009-2017
    • TABLE 201: Rest of Middle East Kidney Cancer Drugs Market Share Breakdown by Pharmacologic Class: 2009 VS 2019 VS 2025
  • AFRICA
    • TABLE 202: African Kidney Cancer Drugs Market Estimates and Projections in US$ Million by Therapeutic Class: 2018 to 2025
    • TABLE 203: Kidney Cancer Drugs Market in Africa by Therapeutic Class: A Historic Review in US$ Million for 2009-2017
    • TABLE 204: African Kidney Cancer Drugs Market Share Breakdown by Therapeutic Class: 2009 VS 2019 VS 2025
    • TABLE 205: African Kidney Cancer Drugs Market Estimates and Projections in US$ Million by Pharmacologic Class: 2018 to 2025
    • TABLE 206: Kidney Cancer Drugs Market in Africa by Pharmacologic Class: A Historic Review in US$ Million for 2009-2017
    • TABLE 207: African Kidney Cancer Drugs Market Share Breakdown by Pharmacologic Class: 2009 VS 2019 VS 2025

IV. COMPETITION

  • BAYER AG
  • BRISTOL-MYERS SQUIBB COMPANY
  • EISAI CO.
  • EXELIXIS, INC.
  • NOVARTIS INTERNATIONAL AG
  • PFIZER, INC

V. CURATED RESEARCH

Back to Top